BioLineRx Ltd. Share Price TEL AVIV STOCK EXCHANGE
Equities
BLRX
IL0011015182
Biotechnology & Medical Research
Sales 2024 * | 14.36M 53.22M 1.2B | Sales 2025 * | 27.77M 103M 2.31B | Capitalization | 52.22M 193M 4.35B |
---|---|---|---|---|---|
Net income 2024 * | -47M -174M -3.91B | Net income 2025 * | -36M -133M -3B | EV / Sales 2024 * | 3.64 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.88 x |
P/E ratio 2024 * |
-2.18
x | P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.64% |
Latest transcript on BioLineRx Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Philip Serlin
CEO | Chief Executive Officer | 63 | 24/09/24 |
Mali Zeevi
DFI | Director of Finance/CFO | 48 | 01/09/01 |
Irit Gliko-Kabir
CTO | Chief Tech/Sci/R&D Officer | - | 01/17/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sandra Panem
BRD | Director/Board Member | 77 | 24/14/24 |
Avraham Molcho
BRD | Director/Board Member | 66 | 01/10/01 |
Aharon Schwartz
CHM | Chairman | 80 | 01/04/01 |
1st Jan change | Capi. | |
---|---|---|
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |